Multiple Myeloma Screening: How It Works, Results and What to Expect

Multiple myeloma screening is not routinely recommended for everyone without symptoms. It usually begins with blood and urine tests when a clinician suspects a plasma cell disorder based on symptoms, examination findings, or abnormal routine laboratory results.

Overview: What Multiple Myeloma Screening Involves

Multiple myeloma screening refers to tests used to look for signs of a plasma cell disorder, particularly when a person has symptoms, unexplained laboratory changes, or a higher-risk precursor condition. Multiple myeloma is a cancer of plasma cells, a type of white blood cell that normally helps the body fight infection by making antibodies.

Unlike some cancers, there is no routine screening program for multiple myeloma for the general public. Testing is usually targeted rather than performed as a standard check-up. A clinician may investigate because of persistent bone pain, fatigue, frequent infections, anemia, kidney problems, elevated calcium, or an unexpectedly high protein level in a blood test.

The goal is not simply to find an abnormal protein. Doctors assess whether abnormal plasma cells are present and whether they are affecting the blood, bones, kidneys, calcium level, or immune system. This careful approach also helps distinguish multiple myeloma from related conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma.

Who May Need Testing and How the Process Works

Testing may be appropriate for people with symptoms or findings that could suggest myeloma, although these signs commonly have other explanations. Relevant symptoms include persistent back, rib or hip pain; unusual tiredness; shortness of breath related to anemia; recurrent infections; unintentional weight loss; increased thirst; constipation; confusion; or a change in kidney function.

A clinician may also order testing after routine blood work shows anemia, high total protein, elevated calcium, reduced kidney function, or a raised erythrocyte sedimentation rate. People with MGUS or smoldering multiple myeloma may have scheduled monitoring because a small proportion can progress over time.

Age, family history and Black ancestry are associated with a higher likelihood of myeloma or its precursor conditions, but these factors alone do not usually lead to routine screening. Decisions about testing should be individualized, especially because an isolated abnormal result can cause understandable concern and often requires further clarification.

• Benefits: targeted testing can identify a treatable cause of symptoms and detect organ effects that need prompt attention.
• Limitations: abnormal proteins can occur in non-cancerous conditions, and several tests may be needed before a clear diagnosis is possible.
• Risks: blood and urine testing has minimal physical risk; bone marrow sampling and contrast imaging have additional, generally manageable risks.

Step by Step: Tests Used in Multiple Myeloma Screening

The first step is usually a medical history, physical examination and blood testing. A complete blood count (CBC) checks red blood cells, white blood cells and platelets. Blood chemistry tests assess kidney function, calcium, albumin, total protein and other measures that can show whether organs may be affected.

Specific protein tests are central to the assessment. Serum protein electrophoresis (SPEP) and immunofixation can identify and characterize a monoclonal protein, sometimes called an M protein or paraprotein. A serum free light chain test measures antibody fragments that may be produced in excess. Urine protein electrophoresis and urine immunofixation, often using a 24-hour urine collection, can detect light chains passing into the urine.

If initial testing raises concern, a hematologist may recommend a bone marrow aspiration and biopsy. Under local anesthetic, a small sample is commonly taken from the back of the pelvic bone and examined for plasma cells and genetic changes. Imaging may include low-dose whole-body CT, MRI or PET-CT to look for bone lesions or areas of active disease.

Most blood draws take only a few minutes, and urine collection is done at home according to laboratory instructions. After a bone marrow biopsy, local soreness or bruising may last for several days. Patients should follow the care team’s instructions about activity, wound care and medicines that may affect bleeding.

What Are the Typical Results of Multiple Myeloma Tests?

Typical results vary depending on the stage and type of plasma cell disorder. In multiple myeloma, testing may show an M protein in blood or urine, an abnormal free light chain ratio, increased plasma cells in the bone marrow, and evidence of organ or bone involvement. However, not every person has the same pattern, and a small number have little or no measurable M protein.

An M protein alone does not mean that a person has multiple myeloma. MGUS can cause a small amount of monoclonal protein without myeloma-related organ damage, while smoldering multiple myeloma has higher levels of abnormal plasma cells or protein but no defining organ injury. These conditions are managed differently and often monitored over time.

Doctors interpret results together rather than relying on one test. They consider the amount and type of M protein, free light chain findings, bone marrow plasma cell percentage, imaging results and whether there are myeloma-defining events. Repeat testing may be needed to confirm a result or understand whether a change is stable, temporary or progressing.

What Is the Biggest Indicator of Multiple Myeloma?

There is no single biggest indicator that confirms multiple myeloma. A monoclonal protein in the blood or urine is a common clue, but it is not specific enough to diagnose the condition on its own. The diagnosis depends on finding abnormal clonal plasma cells or a related protein abnormality together with evidence that the disorder meets established diagnostic criteria.

Clinicians pay particular attention to myeloma-defining events. These include high calcium levels, kidney impairment, anemia and bone lesions, often summarized as CRAB features. Certain biomarker findings, such as a very high proportion of clonal plasma cells in bone marrow or specific high-risk imaging or light chain findings, may also indicate active myeloma before CRAB problems develop.

Because symptoms such as tiredness and back pain are common and may have many causes, they should not be interpreted as proof of myeloma. A timely clinical review and appropriate tests are the safest way to identify the cause.

What Is Stage 1 Multiple Myeloma?

Stage 1 multiple myeloma is an early stage of active disease under the Revised International Staging System (R-ISS), which helps doctors describe prognosis and plan care. Staging is different from screening or diagnosis: it is performed after multiple myeloma has been confirmed.

R-ISS stage 1 generally reflects more favorable levels of certain blood markers, including beta-2 microglobulin and albumin, and the absence of high-risk chromosome changes or a markedly elevated lactate dehydrogenase level. The exact assessment requires specialized laboratory and genetic testing, so patients should ask their hematologist to explain what their individual stage means.

Stage 1 does not mean that treatment is unnecessary. Active myeloma is treated according to the person’s health, symptoms, kidney function, genetic risk, disease features and suitability for treatments such as systemic therapy or stem cell transplantation. Outcomes differ between individuals, and staging is only one part of care planning.

What Would Your CBC Look Like With Multiple Myeloma?

A CBC in multiple myeloma may show anemia, meaning a reduced hemoglobin level or red blood cell count. Anemia can contribute to fatigue, weakness, dizziness or shortness of breath with activity. It can occur when myeloma cells crowd the bone marrow, kidney function is reduced, or inflammation affects red blood cell production.

White blood cell and platelet counts may be normal, especially earlier in the disease. In some cases, they are low because the bone marrow is affected. Low white blood cells can increase susceptibility to infection, while low platelets may contribute to easier bruising or bleeding.

A normal CBC does not rule out multiple myeloma, and abnormal CBC results do not establish the diagnosis. Anemia is very common and can result from iron deficiency, vitamin deficiencies, chronic illness, bleeding, kidney disease and many other conditions. Additional protein tests, chemistry studies and, when indicated, imaging or bone marrow examination provide the needed context.

When to Seek Medical Care

A person should arrange a medical review for persistent, unexplained bone pain, especially in the back, ribs or hips; ongoing fatigue; repeated infections; unexplained weight loss; or abnormal results from routine blood tests. A clinician can assess common causes first and decide whether testing for a plasma cell disorder is appropriate.

More urgent medical assessment is important for severe or rapidly worsening weakness, confusion, severe thirst or dehydration, sudden significant back pain, new numbness or weakness in the legs, loss of bladder or bowel control, fever during an infection, or markedly reduced urine output. These symptoms can have several causes but may require prompt evaluation.

If multiple myeloma is diagnosed, care is usually coordinated by a hematologist or hematologist-oncologist with support from kidney, bone, radiology, pathology and infection specialists as needed. Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals support diagnosis and treatment planning for international patients.

Frequently asked questions

Is there a routine screening test for multiple myeloma?

No. Routine multiple myeloma screening is not generally recommended for people without symptoms or concerning laboratory findings. Testing is usually performed when a clinician identifies symptoms, abnormal blood results, or a known plasma cell precursor condition that needs follow-up.

Can a blood test diagnose multiple myeloma by itself?

Blood tests can provide important evidence, including an M protein or abnormal free light chains, but they usually cannot confirm multiple myeloma alone. Doctors may combine blood and urine testing with bone marrow examination and imaging to make or exclude the diagnosis.

Does a high protein level mean multiple myeloma?

No. High total protein can occur for several reasons, including dehydration, inflammation and some infections. It may prompt further protein testing, but only a full clinical evaluation can determine whether an abnormal monoclonal protein is present and what it means.

How long does it take to get multiple myeloma test results?

Basic blood and urine results may be available within days, depending on the laboratory. Specialized protein studies, bone marrow analysis and genetic tests can take longer, and imaging is scheduled according to clinical urgency. The care team can explain the expected timeline for each test.

Is a bone marrow biopsy always needed?

A bone marrow biopsy is commonly needed when tests strongly suggest multiple myeloma or another plasma cell disorder because it measures plasma cells and can identify important genetic features. It may not be the first test performed, and the decision is based on the initial results and clinical situation.

Can multiple myeloma be found before symptoms begin?

Sometimes. An abnormal monoclonal protein may be discovered incidentally during testing for another reason, leading to identification of MGUS or smoldering multiple myeloma. These conditions do not always need immediate treatment, but they may require planned monitoring.

References

• National Cancer Institute
• International Myeloma Foundation
• American Cancer Society
• National Comprehensive Cancer Network
• Mayo Clinic

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.